Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
Roumy, V.
Ruiz, L.
Ruiz Macedo, J.C.
Gutierrez-Choquevilca, A.-L.
Samaillie, J.
Encinas, L.A.
Mesia, W.R.
Ricopa Cotrina, H.E.
Rivière, C.
Sahpaz, S.
Bordage, S.
Garçon, G.
Dubuisson, J.
Anthérieu, S.
Seron, K.
Hennebelle, T.
Journal of ethnopharmacology, 2020-3
Karin Seron
Seron Karin
ORCID: 0000-0002-9667-133X
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/jvi.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/jvi.01402-14
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity
10.2337/diabetes.55.02.06.db05-0971
Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
10.1016/j.bbrc.2006.07.068
Genetic study of the CD36 gene In a French diabetic population
10.1016/s1262-3636(07)70143-x
GAD2 on chromosome 10p12 is a candidate gene for human obesity
10.1371/journal.pbio.0000068
Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii
10.1046/j.1432-1327.2000.01749.x
Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants
10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase
10.1016/s0166-0934(96)02166-0
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997)
10.1016/s0166-0934(96)02249-5
Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells
10.1006/viro.1996.0246
Gene expression from viral RNA genomes
10.1007/bf00039391
Vascular movement of plant viruses
10.1094/mpmi-9-0435
IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS
10.1016/s0923-2516(06)80049-x
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
10.1016/j.antiviral.2016.07.011
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus
10.1101/325126
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.
10.1016/j.jep.2020.112735
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
10.1021/acsami.9b15032
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes".
10.1128/jvi.00309-18
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
A yeast t-SNARE involved in endocytosis.
10.1091/mbc.9.10.2873
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
vincent roumy
roumy vincent
ORCID: 0000-0002-1402-3460
Neoboutonia melleri var velutina Prain: In vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models
10.1186/s12906-018-2091-2
Antimicrobial activity of selected Iranian medicinal plants against a broad spectrum of pathogenic and drug multiresistant micro-organisms
10.1111/lam.12294
Antiproliferative and Antibacterial Activities of Cirsium scabrum from Tunisia
10.1155/2017/7247016
Rosmarinic acid and its methyl ester as antimicrobial components of the hydromethanolic extract of Hyptis atrorubens Poit. (Lamiaceae)
10.1155/2013/604536
Four anti-protozoal and anti-bacterial compounds from Tapirira guianensis
10.1016/j.phytochem.2008.10.003
Phenolic compounds from humulus lupulus as natural antimicrobial products: New weapons in the fight against methicillin resistant staphylococcus aureus, leishmania mexicana and trypanosoma brucei strains
10.3390/molecules24061024
Plant therapy in the Peruvian Amazon (Loreto) in case of infectious diseases and its antimicrobial evaluation
10.1016/j.jep.2019.112411
Activity-guided isolation of antiplasmodial dihydrochalcones and flavanones from Piper hostmannianum var. berbicense
10.1016/j.phytochem.2007.02.006
Letter: Characterisation and identification of spermine and spermidine derivatives in Microdesmis keayana and Microdesmis puberula roots by electrospray ionisation tandem mass spectrometry and high-performance liquid chromatography/electrospray ionisation tandem mass spectrometry
10.1255/ejms.910
Chemical Composition and Antimicrobial Activity of the Essential Oil from Aerial Parts and Roots of Eryngium barrelieri Boiss. and Eryngium glomeratum Lam. from Tunisia
10.1002/cbdv.201600136
Determination of alkaloids in endemic Genista quadriflora Munby (Fabaceae)
10.1016/j.bse.2014.05.005
Chemotaxonomy and flavonoid profiling of Torilis species by HPLC/ESI/MS2
10.1016/j.bse.2011.07.012
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Humulane and germacrane sesquiterpenes from ferula lycia
10.1021/np900827a
Biocontrol activity of effusol from the extremophile plant, Juncus maritimus, against the wheat pathogen Zymoseptoria tritici
10.1007/s11356-017-9043-0
Aqueous extracts of Syzygium brazzavillense can inhibit the infection with coxsackievirus B4 in vitro
10.1002/jmv.25436
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants
10.1111/jphp.12728
Antifungal and cytotoxic activity of withanolides from acnistus arborescens
10.1021/np100201p
Amazonian plants from Peru used by Quechua and Mestizo to treat malaria with evaluation of their activity
10.1016/j.jep.2007.04.009
Tannins and catechin gallate mediate the vasorelaxant effect of Arbutus unedo on the rat isolated aorta
10.1002/ptr.1513
Activity of ladanein on leukemia cell lines and its occurrence in marrubium vulgare
10.1055/s-0029-1185972
Plants used by native Amazonian groups from the Nanay River (Peru) for the treatment of malaria
10.1016/j.jep.2010.10.039
Antimicrobial and Light-Enhanced Antimicrobial Activities, Cytotoxicity and Chemical Variability of All Tunisian Eryngium Species
10.1002/cbdv.201900543
Isolation and antimalarial activity of alkaloids from Pseudoxandra cuspidata
10.1055/s-2006-947184
Chemical composition of the essential oil from Algerian Genista quadriflora Munby and determination of its antibacterial and antifungal activities
10.1016/j.indcrop.2016.06.016
Antimicrobial prenylated benzoylphloroglucinol derivatives and xanthones from the leaves of Garcinia goudotiana
10.1016/j.phytochem.2014.03.006
Antifungal activity of 10 guadeloupean plants
10.1002/ptr.4906
A new cernuane-type alkaloid from Lycopodium cernuum
10.1016/j.bse.2012.07.026
Coumarins, caffeoyl derivatives and a monoterpenoid glycoside from Ferulago asparagifolia
10.1016/j.bse.2009.03.003
Jean Dubuisson
Dubuisson Jean
ORCID: 0000-0003-1626-7693
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses
10.1016/j.jhep.2015.12.021
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
10.1136/gutjnl-2015-311109
Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats
10.3390/v7122937
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
10.1039/c4nr03875d
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
HCV envelope glycoproteins in virion assembly and entry
10.2217/FVL.14.114
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
10.1128/JVI.00991-15
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice
10.1002/bab.1223
Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
10.1128/JVI.01745-13
HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin
10.3748/wjg.v20.i1.148
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Hepatitis C virus life cycle and lipid metabolism
10.3390/biology3040892
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/JVI.01402-14
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
10.3390/v6031149
Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation
10.1016/j.vaccine.2014.01.046
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Virology and cell biology of the hepatitis C virus life cycle - An update
10.1016/j.jhep.2014.06.031
Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization
10.1093/infdis/jit376
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/JVI.02659-12
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics
10.1021/am403770q
Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies
10.2217/fvl.13.75
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Virus-neutralizing antibodies to hepatitis C virus
10.1111/jvh.12094
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
10.1136/gutjnl-2012-302048
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion
10.1074/jbc.M112.382341
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein
10.1099/vir.0.028092-0
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships
10.1099/vir.0.034314-0
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
HCV replication and assembly: a play in one act
10.2217/FVL.11.69
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
10.1128/JVI.01332-10
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
10.1128/JVI.02170-10
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus
10.1128/JVI.01180-10
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/JVI.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/JVI.01190-09
Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets
10.3390/v2081782
NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus
10.1074/jbc.M110.122895
Recent Advances in Hepatitis C Virus Cell Entry
10.3390/v2030692
Role of lipid metabolism in hepatitis C virus assembly and entry
10.1042/BC20090125
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/JVI.01548-10
Enhanced anti-HCV activity of interferon alpha 17 subtype
10.1186/1743-422X-6-70
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/vir.2009.0270
Occludin, the final essential factor for HCV entry?
10.2217/FVL.09.13
Rapid synchronization of hepatitis C virus infection by magnetic adsorption
10.1016/j.jviromet.2008.11.015
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein
10.1128/JVI.02582-07
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus
10.1086/589777
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
10.1128/JVI.01443-07
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection
10.1128/JVI.01573-06
Hepatitis C virus proteins
10.3748/wjg.v13.i17.2406
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
10.1073/pnas.0705522104
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
10.1186/1742-4690-4-8
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
10.1099/vir.0.82465-0
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes
10.1007/s00232-007-9003-6
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
10.1128/JVI.00127-07
Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry
10.1128/JVI.02198-06
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles
10.1099/vir.0.81503-0
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans
10.1074/jbc.M602431200
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/JVI.00024-06
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI
10.1074/jbc.M602706200
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
10.1099/vir.0.81932-0
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
10.1002/hep.21406
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/JVI.80.6.2832-2841.2006
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2
10.1128/JVI.79.21.13199-13208.2005
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets
10.1099/vir.0.81169-0
Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry
10.1128/JVI.79.24.15331-15341.2005
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/JVI.79.16.10826-10829.2005
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
10.1002/hep.20542
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
10.1099/vir.0.81140-0
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
10.1074/jbc.M411600200
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/S0074-7696(05)45006-8
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins
10.1128/JVI.79.13.8400-8409.2005
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/JVI.78.6.2994-3002.2004
Functional hepatitis C virus envelope glycoproteins
10.1016/j.biolcel.2004.03.008
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions
10.1128/JVI.78.17.9224-9232.2004
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein
10.4049/jimmunol.173.1.446
Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication
10.1007/s00705-003-0291-6
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
Structural biology of hepatitis C virus
10.1002/hep.20032
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/JVI.78.22.12591-12602.2004
Another putative receptor for hepatitis C virus
10.1002/hep.510370327
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/JVI.77.19.10677-10683.2003
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
10.1074/jbc.M305289200
Characterization of the expression of the hepatitis C virus F protein
10.1099/vir.0.19065-0
Glycosylation of hepatitis C virus envelope proteins
10.1016/S0300-9084(03)00004-X
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
10.1084/jem.20021756
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope
10.1128/JVI.77.2.813-820.2003
Topology of hepatitis C virus envelope glycoproteins
10.1002/rmv.391
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines
10.1128/JVI.76.3.1181-1193.2002
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Interaction of hepatitis C virus proteins with host cell membranes and lipids
10.1016/S0962-8924(02)02383-8
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines
10.1006/viro.2001.1212
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment
10.1074/jbc.M111020200
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/JVI.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization
10.1053/jhep.2001.22175
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
10.1128/JVI.75.17.8240-8250.2001
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/JVI.74.8.3623-3633.2000
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding
10.1099/0022-1317-81-12-2873
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
10.1128/JVI.74.2.702-709.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells
10.1046/j.1432-1327.2000.01111.x
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization
10.1074/jbc.M003003200
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex
10.1099/0022-1317-80-4-887
Characterization of aggregates of hepatitis C virus glycoproteins
10.1099/0022-1317-80-12-3099
Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum
10.1023/A:1020228725997
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
10.1006/viro.1998.9202
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
Characterization of truncated forms of hepatitis C virus glycoproteins
10.1099/0022-1317-78-9-2299
SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H
10.1016/S0042-6822(95)80083-2
ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE
10.1006/viro.1993.1471
IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES
10.1007/BF01309747
EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(92)90010-B
IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-73-5-1293
MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV
10.1099/0022-1317-73-8-2031
MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4
10.1016/0378-1135(92)90037-T
PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT
10.1099/0022-1317-73-1-189
A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(91)90133-K
ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-3-715
BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS
10.1016/0378-1135(91)90132-Y
CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM
10.1099/0022-1317-72-5-1195
COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-5-1145
FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63
10.1136/vr.128.26.614
GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES
10.1007/BF01319227
TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS
10.1099/0022-1317-72-6-1429
Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis
10.1099/0022-1317-71-1-133
Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization
10.1099/0022-1317-71-3-647
EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE
10.1016/0378-1135(89)90022-9
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4
10.1016/0378-1135(89)90096-5
PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES
10.1099/0022-1317-70-7-1743
BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS
10.1016/0378-1135(88)90015-6
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly
10.1128/JVI.00048-17
Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination
10.1111/pbi.12743
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly
10.1016/j.biochi.2017.06.009
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics
10.1016/j.jviromet.2017.04.009
Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes
10.1128/JVI.00478-17
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
10.1007/s40271-017-0232-1
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
10.1371/journal.pone.0145105
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
10.1111/jvh.12433
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain
10.1128/JVI.00939-18
HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region
10.1099/jgv.0.001074
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
10.3389/fimmu.2018.00910
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/JVI.02009-18
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
10.1016/j.antiviral.2019.05.002
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E
10.1051/medsci/2018299
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Function of the HCV E1 envelope glycoprotein in viral entry and assembly
10.2217/fvl-2018-0180
Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV
10.1007/978-1-4939-8976-8_2
Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit
10.1016/j.jcv.2019.104206
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
10.1186/s12879-019-4571-5
Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
10.3390/cells8101296
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
10.1021/acsami.9b15032
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.ra119.008964
Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection
10.1111/tra.12680
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
10.1101/2020.04.22.056754
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Les coronavirus, ennemis incertains
10.1051/medsci/2020113
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
10.3390/microorganisms9020339
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds
10.3390/pathogens10070861
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
